SCHEMBL4670645

SCHEMBL4670645

O=C(O)C(O)=CC(=O)c1csc(Cc2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 3/20 0.49
LTB4R Q15722 2/20 0.46
PTGER1 P34995 1/20 0.40
TP53 P04637 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 4/20 0.38
GAA P10253 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PLA2G10 O15496 1/20 0.35
PLA2G2A P14555 1/20 0.35
HDAC1 Q13547 3/20 0.34
HDAC2 Q92769 2/20 0.34
NFE2L2 Q16236 1/20 0.34
HDAC3 O15379 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ABL1 P00519 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670642 1.00 DAO (0.49) DAOLTB4RPTGER1TP53RAB9A
SCHEMBL4671587 0.88 DAO (0.37) DAOLTB4RPTGER1TP53RAB9A
SCHEMBL4674977 0.88 SRD5A2 (0.39) DAOLTB4RTP53RAB9ALMNA
SCHEMBL4679603 0.88 DAO (0.37) DAOLTB4RPTGER1TP53RAB9A
SCHEMBL4674981 0.88 SRD5A2 (0.39) DAOLTB4RTP53RAB9ALMNA
SCHEMBL4671583 0.88 DAO (0.37) DAOLTB4RPTGER1TP53RAB9A
SCHEMBL4679607 0.88 DAO (0.37) DAOLTB4RPTGER1TP53RAB9A
SCHEMBL4673684 0.88 KDM4E (0.38) DAOLTB4RRAB9ALMNAGAA
SCHEMBL4673686 0.88 KDM4E (0.38) DAOLTB4RRAB9ALMNAGAA
SCHEMBL4676364 0.87 DAO (0.40) DAOLTB4RRAB9ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 DAO 661/4885LTB4R 1834/4885PTGER1 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.